A downstream centre in Scotland will allow local biotechs to test product scale-up without outsourcing overseas, while complementing other Government-funded bioprocessing projects in the UK.
The European Commission (EC) has approved Samsung Bioepis’ Remicade (infliximab) biosimilar.
Orgenesis and Atvio have formed a cell therapy contract manufacturing joint venture and are looking to procure a GMP facility in Israel.
Celltrion will invest $275m at its biosimilar production site in Korea to ramp up capacity from 140,000L to 310,000L by 2021.
TxCell has been cleared to restart a Phase IIb trial of its candidate Crohn’s disease cell therapy by European regulators.
Thermo Fisher Scientific is to buy FEI Company for $4.2bn saying it will drive adoption of FEI’s technologies among its life sciences customers, particularly in biopharma.
Content Provided by World Courier
Getting a clinical trial drug into China is a complex business. Any discrepancies in paperwork or the physical shipment can lead to delays at customs or China Inspection & Quarantine. World Courier shares its experience for successful shipping.